Document Detail


CD4(+)CD45RA(+)CXCR4 (+) lymphocytes are inversely associated with progression in stages I-III melanoma patients.
MedLine Citation:
PMID:  19779716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The chemokine receptor CXCR4 was described as an independent predictor of poor prognosis in primary human melanoma. To investigate on a possible role of CXCR4 expression on peripheral blood lymphocytes (PBL) subsets, 195 patients with melanoma were evaluated for correlations between PBL subsets CXCR4 expressing and clinicopathological and prognostic features. One hundred ninety-five patients with stages I-III melanoma were enrolled in this study. Lymphocytes subsets were assayed by the direct fluorescence method for whole blood and staining with fluorochrome-conjugated monoclonal antibodies. Correlations between PBL subsets, baseline patient, and tumor features were studied by contingency tables and the chi(2) test. The Kaplan-Meier product limit method was applied to plot disease-free- and overall-survival curves. Univariate analysis was performed with the log-rank test. Cox proportional-hazards regression was used to analyze the effect of multiple risk factors on disease-free survival (DFS). Melanoma patients characterized by CD4(+)CD45RA(+)CXCR4(+) higher than 25% of PBL showed a longer DFS. Conversely, CD4(+)CD45RA(+)CXCR4(+) <25% increased the risk of relapse. The 5-year DFS rate was 76% for patients with CD4(+)CD45RA(+)CXCR4(+) lymphocytes <25% of PBL, and 94% for patients with CD4(+)CD45RA(+)CXCR4(+) >25% (p = 0.030 at log-rank test). Univariate and multivariate analysis for DFS confirmed the prognostic value of the CD4(+)CD45RA(+)CXCR4(+) lymphocytes. Although further studies are needed to better define the involved subpopulation, the detection of cellular subset CD4(+)CD45RA(+)CXCR4(+) is an easy and feasible evaluation of melanoma patients in concomitance with the established melanoma prognostic markers.
Authors:
Maria Napolitano; Alessandro Ottaiano; Francesca Mauro; Caterina Ieran?; Rocco Satriano; Roberto Pacelli; Renato Franco; Valentina De Angelis; Giuseppe Castello; Stefania Scala
Related Documents :
1247956 - Malignant melanoma. role of node dissection reappraised.
18318916 - Extensive necrosis of visceral melanoma metastases after immunotherapy.
11004266 - Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocu...
10424306 - Survival following enucleation versus plaque radiotherapy in statistically matched subg...
15191206 - Pancreatic carcinoma with brain metastases: case report and literature review.
455236 - Anaplastic seminoma: an analysis of 77 patients.
Publication Detail:
Type:  Journal Article     Date:  2009-09-25
Journal Detail:
Title:  Cancer immunology, immunotherapy : CII     Volume:  59     ISSN:  1432-0851     ISO Abbreviation:  Cancer Immunol. Immunother.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-01-29     Completed Date:  2010-02-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8605732     Medline TA:  Cancer Immunol Immunother     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  511-7     Citation Subset:  IM    
Affiliation:
Department of Clinical Immunology, National Cancer Institute, G. Pascale Foundation, via Mariano Semmola, 80131 Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antigens, CD45 / metabolism*
CD4-Positive T-Lymphocytes / immunology*
Disease Progression
Female
Flow Cytometry
Follow-Up Studies
Humans
Male
Melanoma / immunology*,  metabolism
Middle Aged
Neoplasm Staging
Prognosis
Prospective Studies
Receptors, CXCR4 / metabolism*
Skin Neoplasms / immunology*,  metabolism
Survival Rate
Young Adult
Chemical
Reg. No./Substance:
0/CXCR4 protein, human; 0/Receptors, CXCR4; EC 3.1.3.48/Antigens, CD45

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 an...
Next Document:  High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial i...